Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials

Highlights • SGLT-2 inhibitors are capable of stimulating the release of glucagon and ketone re-absorption in the renal tubuli, increasing the risk of ketoacidosis. • Ketoacidosis during treatment with SGLT2 inhibitors is a relevant acidosis and ketosis with only mild hyperglycemia, which may repres...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes research and clinical practice 2017-08, Vol.130, p.53-60
Hauptverfasser:	Monami, Matteo, PhD,MD, Nreu, Besmir, MD, Zannoni, Stefania, MD, Lualdi, Carlotta, MD, Mannucci, Edoardo, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes Mellitus, Type 2 - drug therapy Diabetic Ketoacidosis - drug therapy Endocrinology & Metabolism Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Ketoacidosis Meta-analysis Randomized clinical trials Randomized Controlled Trials as Topic Serious adverse events SGLT2 inhibitor Sodium-Glucose Transporter 2 - antagonists & inhibitors Treatment Outcome Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • SGLT-2 inhibitors are capable of stimulating the release of glucagon and ketone re-absorption in the renal tubuli, increasing the risk of ketoacidosis. • Ketoacidosis during treatment with SGLT2 inhibitors is a relevant acidosis and ketosis with only mild hyperglycemia, which may represent an obstacle for a correct diagnosis. • The present meta-analysis shows that if the drug is properly prescribed, the risk of DKA is negligible in patients with type 2 diabetes.
ISSN:	0168-8227 1872-8227
DOI:	10.1016/j.diabres.2017.04.017